Developer docs
API playgroundTry for free, no card

Search company profiles

Byondis

Full company profile

uuid0008jas

Namestring
Byondis
Legal namestring
Byondis B.V.
Websiteurl
byondis.com
Company typeenum
Private
Founded yearint
2007
Short descriptiontext

Byondis is a Dutch biopharmaceutical company developing proprietary antibody-drug conjugate (ADC) technology platforms for cancer treatment; following its December 2025 strategic transformation, it focuses on licensing these platforms and partnered programs rather than independent clinical development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNijmegen, Netherlands
HQ citystring
Nijmegen
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, oncology biopharmaceuticals, targeted cancer therapy, ADC linker-drug platforms, immuno-oncology medicines
Industry3 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals / Antibody-Drug Conjugates
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Royalties
TypeLicensing Royalties
Description

Byondis generates revenue through licensing agreements for its ADC technologies and pipeline assets. The company receives upfront payments, sales royalties, and milestone payments upon achievement of development and sales targets. Partner medac has exclusive license to commercialize SYD985 in EU, UK and other European countries.

byondis.com
2Drug Development and Commercialization
TypeLicensing Royalties
Description

As a clinical-stage biopharmaceutical company, Byondis develops proprietary ADC therapies through clinical stages with the intention of partnering or commercializing directly upon regulatory approval.

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Byondis is a biopharmaceutical company developing proprietary antibody-drug conjugate (ADC) technology platforms and targeted precision medicines for intractable cancers and autoimmune diseases. The company operates fully integrated in-house R&D and GMP manufacturing facilities in Nijmegen, Netherlands, and after a December 2025 strategic transformation is focused on licensing and partnering its ADC platforms (ByonZine®, ByonNative®, ByonShieLD®, ByonFoLD®, ByonBranch®, ByonGuard™, ByonBoost™, and the Antifolate Linker-Drug Platform) to pharmaceutical and biotech partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase III TULIP study demonstrated 7.0 months median PFS for SYD985 vs 4.9 months for physician's choice (HR 0.64, p=0.002)
+2 more records
Product overview1 text field

Byondis is a fully integrated Dutch biopharmaceutical company developing targeted cancer medicines, primarily antibody-drug conjugates (ADCs) and monoclonal antibodies. The company's portfolio is organized around proprietary technology platforms — including ByonZine® (duocarmazine linker-drug), ByonShieLD® (site-specific conjugation), ByonNative®, ByonFoLD® (dual-payload), ByonBranch® (branched linker), ByonGuard™ (universal masking), ByonBoost™ (phosphonate immunostimulatory), and an Antifolate linker-drug platform — which collectively generate pipeline candidates. Clinical-stage programs include SYD985 ([vic-]trastuzumab duocarmazine) targeting HER2-positive cancers, BYON3521 (c-MET-targeting ADC), and previously BYON4228 and BYON4413 prior to discontinuation in the December 2025 strategic transformation. The company operates fully integrated in-house R&D and GMP manufacturing facilities in Nijmegen, the Netherlands.

Product and service11 records
1SYD985 ([vic-]Trastuzumab Duocarmazine)
CategoryAntibody-Drug Conjugate (Clinical Stage)
Description

Next-generation anti-HER2 antibody-drug conjugate (ADC) using Byondis' proprietary ByonZine® duocarmazine linker-drug technology for HER2-positive metastatic breast cancer and other HER2-expressing cancers. Licensed to medac GmbH for European commercialization.

2BYON3521
CategoryAntibody-Drug Conjugate (Clinical Stage)
Description

c-MET-targeting antibody-drug conjugate using site-specific ByonShieLD® conjugation and ByonZine® linker-drug technology, in Phase I clinical study for c-MET-expressing solid tumors.

3SYD1875
CategoryAntibody-Drug Conjugate (Clinical Stage)
Description

Next-generation antibody-drug conjugate targeting the 5T4 oncofetal antigen using Byondis' proprietary vc-seco-DUBA linker-drug and site-specific HC-41C conjugation technology, in Phase I study for 5T4-expressing solid tumors.

4ByonZine® Linker-Drug Technology Platform
CategoryADC Technology Platform (Licensable)
Description

Proprietary cleavable DNA-damaging duocarmazine linker-drug platform enabling ADCs to eliminate heterogeneous tumors via target-mediated and bystander mechanisms, killing both dividing and non-dividing cancer cells with extremely low free-drug levels in circulation. Available for licensing to ADC developers.

5ByonNative® Antibody Conjugation Platform
CategoryADC Technology Platform (Licensable)
Description

Differentiated antibody conjugation platform enabling ADC generation via partially reduced native disulfide bonds with proprietary process to remove unwanted non-conjugated and over-conjugated species, enabling rapid generation of ByonZine® ADCs.

6ByonShieLD® Site-Specific Conjugation Platform
CategoryADC Technology Platform (Licensable)
Description

Site-specific antibody conjugation platform creating uniform ByonZine® ADCs via orthogonal cysteine activation and conjugation; shielding of hydrophobic payload yields ADCs with superior therapeutic index and manufacturability.

7ByonFoLD® Dual Linker-Drug Platform
CategoryADC Technology Platform (Licensable)
Description

Dual linker-drug antibody conjugation platform producing well-defined two-in-one ADCs in which two different payloads are conjugated compatibly to a single antibody, enabling next-generation ADCs with synergistically operating dual payloads.

8ByonBranch® Branched Linker Technology
CategoryADC Technology Platform (Licensable)
Description

Branched linker technology allowing coupling of payloads to an antibody resulting in ADCs with reduced hydrophobicity.

9ByonGuard™ Universal Masking Platform
CategoryADC Technology Platform (Licensable)
Description

Universal masking platform designed to improve therapeutic index of antibody-based therapies by limiting binding in healthy tissues and restoring full target engagement in tumors, with no bespoke peptides required.

10ByonBoost™ Phosphonate Linker-Drug Platform
CategoryADC Technology Platform (Licensable)
Description

Phosphonate linker-drug platform engineered to activate Vγ9Vδ2 (γδ) T cells in the tumor microenvironment, enabling targeted delivery with immunologic anti-tumor effect; compatible with single- and dual-payload concepts for solid oncology and hematological malignancies.

11Antifolate Linker-Drug Platform
CategoryADC Technology Platform (Licensable)
Description

ADC linker-drug platform providing a differentiated mechanism targeting dihydrofolate reductase (DHFR), designed to overcome resistance and systemic side effects of current ADC treatments, with broad applicability across treatment lines and tumor types. Available for licensing.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-05-03
Description

License and Collaboration Agreement with Supply Agreement. medac receives exclusive license to commercialize SYD985 in EU, UK, and further European countries (Iceland, Liechtenstein, Norway, Switzerland) in all approved indications. Byondis receives undisclosed upfront payment, sales royalties, and milestone payments upon achievement of development and sales targets. medac will be the marketing authorization applicant for European markets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-27
Description

Platform access agreement for discovery and development of antibodies against novel GlycoTargets. Byondis gains exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets with option to in-license for ADC development. Glycotope's tumor-specific carbohydrate antibodies combined with Byondis' linker-drug platforms aim to produce novel ADC treatments.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-08-25
Description

Phase I study (SYD985.004) exploring synergistic effects of SYD985 in combination with PARP inhibitor niraparib. Niraparib supplied for clinical trial evaluation in HER2-expressing solid tumors.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-07-07
Description

Collaboration for I-SPY 2 TRIAL investigating neoadjuvant use of SYD985 in HER2-low early-stage breast cancer. Quantum Leap provides clinical sites and expertise while Byondis supplies investigational drug and financial/regulatory support. Quantum Leap leads pre-competitive consortium including FDA, industry, patient advocates, and clinicians from 16 major US cancer research centers.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage ADC company with approved Zynlonta and a pipeline built around proprietary pyrrolobenzodiazepine (PBD) payloads. Comparable as a focused ADC platform company developing multiple candidates with differentiated linker-drug technology.

TypeDirect peer
Description

Clinical-stage ADC developer with proprietary payload and conjugation platforms (Dolasynthen, Immunosynthen). Directly comparable as a similarly-sized private/public ADC platform company pursuing differentiated linker-payload chemistries.

TypeBroad incumbent
Description

Global leader in ADC technology (DXd platform underlying Enhertu and Datroway). Comparable as the dominant ADC platform incumbent whose linker-payload IP sets the benchmark Byondis' platforms must differentiate against.

TypeEmerging player
Description

European ADC biotech developing proprietary conjugation platforms (P5 and TAAP) for tunable ADCs with improved stability and therapeutic index. Comparable as a smaller ADC platform company with proprietary linker and conjugation IP targeting differentiated ADC design.

TypeEmerging player
Description

Early-to-mid-stage ADC developer with multiple programs and proprietary conjugation approaches. Comparable as a smaller ADC platform company pursuing novel payloads and tumor-targeting strategies.

TypeEmerging player
Description

Clinical-stage ADC company with proprietary hydrophilic linker technology (ProLinker) and topoisomerase-based payloads. Comparable as an emerging ADC platform developer focused on improving therapeutic index through differentiated linker chemistry.

TypeBroad incumbent
Description

Pioneer of ADC technology and originator of the DM4/DM1 maytansinoid platforms; now part of AbbVie. Comparable as an established ADC platform player with multiple approved ADCs and a deep pipeline of linker-payload programs.

TypeRegional player
Description

China-based ADC-focused CDMO offering end-to-end discovery, development, and manufacturing services for ADCs. Comparable as a regional player offering integrated ADC capabilities, although positioned as a contract manufacturer rather than product developer.

TypeRegional player
Description

Chinese biopharmaceutical company with multiple ADC candidates in clinical development, including collaborations leveraging proprietary payloads. Comparable as a regional player building an oncology franchise with ADC pipeline depth.

TypeDirect peer
Description

German ADC developer commercializing the proprietary amanitin payload platform (ATAC technology). Directly comparable as a European ADC platform player with proprietary payloads targeting novel mechanisms of action.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Byondis

Oncology Biopharmaceuticals / Antibody-Drug Conjugatesbyondis.com

Byondis is a Dutch biopharmaceutical company developing proprietary antibody-drug conjugate (ADC) technology platforms for cancer treatment; following its December 2025 strategic transformation, it focuses on licensing these platforms and partnered programs rather than independent clinical development.

Byondis firmographics

Firmographics
Name
Byondis
Legal name
Byondis B.V.
Website
https://byondis.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
Byondis is a Dutch biopharmaceutical company developing proprietary antibody-drug conjugate (ADC) technology platforms for cancer treatment; following its December 2025 strategic transformation, it focuses on licensing these platforms and partnered programs rather than independent clinical development.
Ownership category
akta.pro rank

Byondis industry classification

Industry
Product category
Oncology Biopharmaceuticals / Antibody-Drug Conjugates
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Antibody-drug conjugates
  • Oncology biopharmaceuticals
  • Targeted cancer therapy
  • ADC linker-drug platforms
  • Immuno-oncology medicines

Where Byondis is headquartered

Location

Headquarters

HQ city
Nijmegen
HQ country
Netherlands
HQ region
Europe

Offices3 records

Markets served

Byondis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Licensing and Royalties: Byondis generates revenue through licensing agreements for its ADC technologies and pipeline assets. The company receives upfront payments, sales royalties, and milestone payments upon achievement of development and sales targets. Partner medac has exclusive license to commercialize SYD985 in EU, UK and other European countries.
  2. Drug Development and Commercialization: As a clinical-stage biopharmaceutical company, Byondis develops proprietary ADC therapies through clinical stages with the intention of partnering or commercializing directly upon regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Byondis product offering

Product offering

Core offering

Byondis is a biopharmaceutical company developing proprietary antibody-drug conjugate (ADC) technology platforms and targeted precision medicines for intractable cancers and autoimmune diseases. The company operates fully integrated in-house R&D and GMP manufacturing facilities in Nijmegen, Netherlands, and after a December 2025 strategic transformation is focused on licensing and partnering its ADC platforms (ByonZine®, ByonNative®, ByonShieLD®, ByonFoLD®, ByonBranch®, ByonGuard™, ByonBoost™, and the Antifolate Linker-Drug Platform) to pharmaceutical and biotech partners.

Product overview

Byondis is a fully integrated Dutch biopharmaceutical company developing targeted cancer medicines, primarily antibody-drug conjugates (ADCs) and monoclonal antibodies. The company's portfolio is organized around proprietary technology platforms — including ByonZine® (duocarmazine linker-drug), ByonShieLD® (site-specific conjugation), ByonNative®, ByonFoLD® (dual-payload), ByonBranch® (branched linker), ByonGuard™ (universal masking), ByonBoost™ (phosphonate immunostimulatory), and an Antifolate linker-drug platform — which collectively generate pipeline candidates. Clinical-stage programs include SYD985 ([vic-]trastuzumab duocarmazine) targeting HER2-positive cancers, BYON3521 (c-MET-targeting ADC), and previously BYON4228 and BYON4413 prior to discontinuation in the December 2025 strategic transformation. The company operates fully integrated in-house R&D and GMP manufacturing facilities in Nijmegen, the Netherlands.

Differentiator

Problem solved

Functional benefit

Products and services

  • SYD985 ([vic-]Trastuzumab Duocarmazine) Next-generation anti-HER2 antibody-drug conjugate (ADC) using Byondis' proprietary ByonZine® duocarmazine linker-drug technology for HER2-positive metastatic breast cancer and other HER2-expressing cancers. Licensed to medac GmbH for European commercialization.
  • BYON3521 c-MET-targeting antibody-drug conjugate using site-specific ByonShieLD® conjugation and ByonZine® linker-drug technology, in Phase I clinical study for c-MET-expressing solid tumors.
  • SYD1875 Next-generation antibody-drug conjugate targeting the 5T4 oncofetal antigen using Byondis' proprietary vc-seco-DUBA linker-drug and site-specific HC-41C conjugation technology, in Phase I study for 5T4-expressing solid tumors.
  • ByonZine® Linker-Drug Technology Platform Proprietary cleavable DNA-damaging duocarmazine linker-drug platform enabling ADCs to eliminate heterogeneous tumors via target-mediated and bystander mechanisms, killing both dividing and non-dividing cancer cells with extremely low free-drug levels in circulation. Available for licensing to ADC developers.
  • ByonNative® Antibody Conjugation Platform Differentiated antibody conjugation platform enabling ADC generation via partially reduced native disulfide bonds with proprietary process to remove unwanted non-conjugated and over-conjugated species, enabling rapid generation of ByonZine® ADCs.
  • ByonShieLD® Site-Specific Conjugation Platform Site-specific antibody conjugation platform creating uniform ByonZine® ADCs via orthogonal cysteine activation and conjugation; shielding of hydrophobic payload yields ADCs with superior therapeutic index and manufacturability.
  • ByonFoLD® Dual Linker-Drug Platform Dual linker-drug antibody conjugation platform producing well-defined two-in-one ADCs in which two different payloads are conjugated compatibly to a single antibody, enabling next-generation ADCs with synergistically operating dual payloads.
  • ByonBranch® Branched Linker Technology Branched linker technology allowing coupling of payloads to an antibody resulting in ADCs with reduced hydrophobicity.
  • ByonGuard™ Universal Masking Platform Universal masking platform designed to improve therapeutic index of antibody-based therapies by limiting binding in healthy tissues and restoring full target engagement in tumors, with no bespoke peptides required.
  • ByonBoost™ Phosphonate Linker-Drug Platform Phosphonate linker-drug platform engineered to activate Vγ9Vδ2 (γδ) T cells in the tumor microenvironment, enabling targeted delivery with immunologic anti-tumor effect; compatible with single- and dual-payload concepts for solid oncology and hematological malignancies.
  • Antifolate Linker-Drug Platform ADC linker-drug platform providing a differentiated mechanism targeting dihydrofolate reductase (DHFR), designed to overcome resistance and systemic side effects of current ADC treatments, with broad applicability across treatment lines and tumor types. Available for licensing.

Quantifiable outcome

  • Phase III TULIP study demonstrated 7.0 months median PFS for SYD985 vs 4.9 months for physician's choice (HR 0.64, p=0.002)
  • +2 more outcomes

Companies that use Byondis

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Byondis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Byondis partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, minor and major.

  • medac GmbHcoreChannel Partner/ Reseller/ Distributor · 3 May 2022License and Collaboration Agreement with Supply Agreement. medac receives exclusive license to commercialize SYD985 in EU, UK, and further European countries (Iceland, Liechtenstein, Norway, Switzerland) in all approved indications. Byondis receives undisclosed upfront payment, sales royalties, and milestone payments upon achievement of development and sales targets. medac will be the marketing authorization applicant for European markets.
  • GlycotopecoreStrategic or Co-development Partner · 27 July 2021Platform access agreement for discovery and development of antibodies against novel GlycoTargets. Byondis gains exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets with option to in-license for ADC development. Glycotope's tumor-specific carbohydrate antibodies combined with Byondis' linker-drug platforms aim to produce novel ADC treatments.
  • GlaxoSmithKline (Niraparib supply)minorStrategic or Co-development Partner · 25 August 2020Phase I study (SYD985.004) exploring synergistic effects of SYD985 in combination with PARP inhibitor niraparib. Niraparib supplied for clinical trial evaluation in HER2-expressing solid tumors.
  • Quantum Leap Healthcare CollaborativemajorStrategic or Co-development Partner · 7 July 2020Collaboration for I-SPY 2 TRIAL investigating neoadjuvant use of SYD985 in HER2-low early-stage breast cancer. Quantum Leap provides clinical sites and expertise while Byondis supplies investigational drug and financial/regulatory support. Quantum Leap leads pre-competitive consortium including FDA, industry, patient advocates, and clinicians from 16 major US cancer research centers.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Byondis competitors and assessment

Company assessment

Direct peers

  • ADC Therapeutics: Commercial-stage ADC company with approved Zynlonta and a pipeline built around proprietary pyrrolobenzodiazepine (PBD) payloads. Comparable as a focused ADC platform company developing multiple candidates with differentiated linker-drug technology.
  • Mersana Therapeutics: Clinical-stage ADC developer with proprietary payload and conjugation platforms (Dolasynthen, Immunosynthen). Directly comparable as a similarly-sized private/public ADC platform company pursuing differentiated linker-payload chemistries.
  • Heidelberg Pharma: German ADC developer commercializing the proprietary amanitin payload platform (ATAC technology). Directly comparable as a European ADC platform player with proprietary payloads targeting novel mechanisms of action.

Broad incumbents

  • Daiichi Sankyo: Global leader in ADC technology (DXd platform underlying Enhertu and Datroway). Comparable as the dominant ADC platform incumbent whose linker-payload IP sets the benchmark Byondis' platforms must differentiate against.
  • ImmunoGen (AbbVie): Pioneer of ADC technology and originator of the DM4/DM1 maytansinoid platforms; now part of AbbVie. Comparable as an established ADC platform player with multiple approved ADCs and a deep pipeline of linker-payload programs.

Emerging players

  • Tubulis: European ADC biotech developing proprietary conjugation platforms (P5 and TAAP) for tunable ADCs with improved stability and therapeutic index. Comparable as a smaller ADC platform company with proprietary linker and conjugation IP targeting differentiated ADC design.
  • Pyxis Oncology: Early-to-mid-stage ADC developer with multiple programs and proprietary conjugation approaches. Comparable as a smaller ADC platform company pursuing novel payloads and tumor-targeting strategies.
  • ProfoundBio: Clinical-stage ADC company with proprietary hydrophilic linker technology (ProLinker) and topoisomerase-based payloads. Comparable as an emerging ADC platform developer focused on improving therapeutic index through differentiated linker chemistry.

Regional players

  • WuXi XDC: China-based ADC-focused CDMO offering end-to-end discovery, development, and manufacturing services for ADCs. Comparable as a regional player offering integrated ADC capabilities, although positioned as a contract manufacturer rather than product developer.
  • Innovent Biologics: Chinese biopharmaceutical company with multiple ADC candidates in clinical development, including collaborations leveraging proprietary payloads. Comparable as a regional player building an oncology franchise with ADC pipeline depth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Byondis social profiles

Digital presence

Byondis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Byondis leadership team

Management profile

Number of profiles

Profiles11 records

Byondis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Byondis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Byondis

What does Byondis do?

Byondis is a biopharmaceutical company developing proprietary antibody-drug conjugate (ADC) technology platforms and targeted precision medicines for intractable cancers and autoimmune diseases. The company operates fully integrated in-house R&D and GMP manufacturing facilities in Nijmegen, Netherlands, and after a December 2025 strategic transformation is focused on licensing and partnering its ADC platforms (ByonZine®, ByonNative®, ByonShieLD®, ByonFoLD®, ByonBranch®, ByonGuard™, ByonBoost™, and the Antifolate Linker-Drug Platform) to pharmaceutical and biotech partners.

Is Byondis a public or private company?

Byondis is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Byondis founded?

Byondis was founded in 2007. It employs 101 to 250 people.

Where is Byondis based?

Byondis is headquartered in Nijmegen, Netherlands, in the Europe region.

How does Byondis make money?

Two revenue lines are on record. Licensing and Royalties are the primary driver. The others are drug Development and Commercialization.

Who are Byondis's main competitors?

Direct peers on record are ADC Therapeutics, Mersana Therapeutics and Heidelberg Pharma. Broad incumbents are Daiichi Sankyo and ImmunoGen (AbbVie). Emerging players are Tubulis, Pyxis Oncology and ProfoundBio. Regional players are WuXi XDC and Innovent Biologics.

Does Byondis have an API?

No public API is recorded for Byondis.

What industry is Byondis in?

Byondis's product category is Oncology Biopharmaceuticals / Antibody-Drug Conjugates. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireByondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC DevelopmentByondis B.V., a Dutch biopharmaceutical company focused on targeted cancer medicines, announced the formation of a Scientific Advisory Board comprising internationally recognized experts in oncology research and antibody-drug conjugate (ADC) development. The advisory board includes notable figures such as Dr. Anthony Tolcher, Dr. John Lambert, Dr. Kapil Dhingra, and Professor Paul Parren, who bring decades of combined experience including contributions to FDA-approved therapies such as Kadcyla and Keytruda. The formation supports Byondis' focused strategy to develop innovative ADC therapies through its proprietary technology platforms and advance its differentiated oncology pipeline.BioSpaceByondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC DevelopmentByondis announced the formation of its Scientific Advisory Board to support its ADC pipeline, appointing experts including Dr. Anthony Tolcher, Dr. John Lambert, Dr. Kapil Dhingra, and Prof. Paul Parren. The board will provide strategic and scientific counsel on precision oncology. The company aims to develop differentiated ADC therapies using its proprietary platform technologies.Business Wire BlogByondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026Byondis B.V. will present data on its novel antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms at the AACR Annual Meeting 2026 in San Diego. The antifolate platform is designed to overcome resistance to current ADC treatments through a differentiated mechanism targeting dihydrofolate reductase, while the phosphonate platform (ByonBoost™) enables inside-out activation of Vγ9Vδ2 T cells for targeted tumor cell killing. Both platforms demonstrate strong preclinical activity with no significant toxicity at active doses, positioning them for potential use across multiple treatment lines and tumor types.AETOSWireOrthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug ProgramOrthogon Therapeutics closed an $11 million follow-on financing, bringing total capital to $36 million. The funds support its first-in-class oral antiviral targeting BK polyomavirus, which causes complications in transplant patients with no approved treatments. The program will be featured at leading meetings in 2026.AETOSWireByondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026...Byondis will present its first-in-class antifolate and phosphonate ADC platforms at the AACR 2026 meeting in San Diego. The antifolate ADC showed tumor regressions in NSCLC and HNSCC models, while the phosphonate platform activated Vγ9Vδ2 T cells in preclinical studies. Both platforms aim to address resistance and immune-therapy failures.AETOSWireiCAUR to Convene Global Partners at 2026 International Business Summit in ChinaiCAUR will host its 2026 International Business Summit in Wuhu this April, featuring a Global Classic Journey on Golden REEV and off-road testing at Longshan. The event also includes lifestyle exhibitions and AIMOGA robots, with a Beijing Auto Show appearance.BioSpaceByondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026Byondis will present its first-in-class antifolate and phosphonate antibody-drug conjugate platforms at the AACR Annual Meeting 2026 in San Diego. The antifolate platform targets acquired resistance, while the phosphonate platform activates Vγ9Vδ2 T cells for immunotherapy. Both platforms are described as differentiated and scalable.BioSpaceADDING MULTIMEDIA Byondis Appoints Christoph Korpus, PhD, MBA as Chief Executive OfficerByondis appointed Christoph Korpus as CEO effective immediately, succeeding founder Jacques Lemmens, who remains chairman. Korpus, previously CBO since January 2025, will lead R&D for the company's ADC technology platforms, including ByonGuard and ByonBoost.Business Wire IndiaByondis Appoints Christoph Korpus, PhD, MBA as Chief Executive OfficerByondis B.V., a Dutch biopharmaceutical company focused on antibody-drug conjugate (ADC) therapies for cancer, has appointed Christoph Korpus as its new Chief Executive Officer, effective immediately, succeeding company founder Jacques Lemmens. Korpus, who previously served as Chief Business Officer since January 2025, will guide the advancement of the company's proprietary ADC technology platforms including ByonGuard™ and ByonBoost™. Lemmens will remain as Chairman of the Board of Directors.